Seminars in Nuclear Medicine
Volume 40, Issue 5 , Pages 364-384, September 2010

Food and Drug Administration Requirements for Testing and Approval of New Radiopharmaceuticals

  • Ravi S. Harapanhalli, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ravi S. Harapanhalli, PhD, Principal Consultant and Practice Lead for Late-Stage Development Consulting, PAREXEL Consulting, 4600 East-West Highway, Bethesda, MD 20814

Principal Consultant and Practice Lead for Late-Stage Development Consulting, PAREXEL Consulting, Bethesda, MD

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Former Branch Chief, Office of New Drug Quality Assessment, CDER, FDA.

PII: S0001-2998(10)00047-4

doi:10.1053/j.semnuclmed.2010.05.002

Seminars in Nuclear Medicine
Volume 40, Issue 5 , Pages 364-384, September 2010

Article Tools

* Image Usage & Resolution